대한약학회 춘계총회 및 학술대회 (2010년) Cost-Effectiveness Analysis of Erlotinib versus Docetaxel as a Second or Third Line Treatment of Non Small Cell Lung Cancer in Korea

학술대회자료

Cost-Effectiveness Analysis of Erlotinib versus Docetaxel as a Second or Third Line Treatment of Non Small Cell Lung Cancer in Korea

대한약학회
춘계총회 및 학술대회
(2010년)
2010.04

250 - 250 (1 pages)

원문보기

원문저장

Cost-Effectiveness Analysis of Erlotinib versus Docetaxel as a Second or Third Line Treatment of Non Small Cell Lung Cancer in Korea

(0)

(0)

(0)

(0)

Cost-Effectiveness Analysis of Erlotinib versus Docetaxel as a Second or Third Line Treatment of Non Small Cell Lung Cancer in Korea

(0)

(0) 팝업 열기 팝업 닫기

(0)

(0)

(0)